GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Inventories, Raw Materials & Components

MDXXF (Pharmala Biotech Holdings) Inventories, Raw Materials & Components : $0.00 Mil (As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Inventories, Raw Materials & Components?

Pharmala Biotech Holdings's inventories, raw materials & components for the quarter that ended in Nov. 2024 was $0.00 Mil.


Pharmala Biotech Holdings Inventories, Raw Materials & Components Historical Data

The historical data trend for Pharmala Biotech Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Inventories, Raw Materials & Components Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Inventories, Raw Materials & Components
- - - -

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmala Biotech Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Pharmala Biotech Holdings Business Description

Industry
Traded in Other Exchanges
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.